The Germany tulathromycin market size has witnessed significant growth in the past and is expected to grow at a CAGR of 5.0% during the forecast period (2022–2030). An antibiotic called tulathromycin treats respiratory diseases in dairy cattle and swine. The patent in the United States, Germany, Canada, and Australia expires in February 2021. Till 2023, the active component tulathromycin is protected in Japan.
Tulathromycin is covered by Zoetis' intellectual property rights (IPR), and it is marketed as Draxxin. The high prevalence of BRD and SRD drives the tulathromycin market. The entry of generic tulathromycin acts as a restraint on this market. On the other hand, a lucrative opportunity for new entrants in generic tulathromycin acts as an opportunity for the tulathromycin market.
BRD is the most common pathology in young and adult animals, affecting 20–25% of calves annually, 10% of which experience growth retardation, and up to 6% die. Swine can also have an SRD prevalence rate of around 20%, with a mortality rate of up to 20% and a risk of sequelae in up to 40% of affected animals. Beyond the effects on animal health, BRD and SRD have a significant financial impact on the farmer because of the reduction in animal growth, the expense of diagnosis and treatment, mortality, and the cost of additional work.
Two generic tulathromycin injectable medicines have just received FDA approval in 2021 for the treatment and management of specific diseases in both cattle and swine. Bovine respiratory disease (BRD) caused by Mannheimia haemolytica, Pasteurella multocida, Histophilus somni, and Mycoplasma bovis is treated with the generic drugs Macrosyn and Increxxa in beef and non-lactating dairy cattle, suckling calves, dairy calves, and veal calves. Additionally, it's used to treat swine respiratory disease (SRD), which is a condition that affects swine and is brought on by pathogens like Actinobacillus pleuropneumoniae, Pasteurella multocida, Bordetella bronchiseptica, Haemophilus parasuis, and Mycoplasma hyopneumoniae.
The approved brand-name drug product Draxxin, first approved in 2005, shares the same active component (tulathromycin) with Macrosyn and Increxxa in the same dose form and concentration. These two generic medications are anticipated to reduce the demand for tulathromycin market in the next few years. By consuming some of the demand for the name-brand Draxxin, the demand for generic medicines will increase more quickly.
The formulation of Draxxin, which contains the active component tulathromycin, is protected by patents in Germany and other important markets. Products containing generic tulathromycin are sold in a few nations, including Colombia, Vietnam, Belarus, Russia, Poland, and Croatia. Marketing permits for products containing generic tulathromycin.
This provides the participants with a lucrative opportunity to enter the industry and take advantage of the growth opportunity, particularly in the United States and Germany. Due to the high end-user spending power and greater reliance on beef and dairy cattle, the U.S. and Germany are the two largest markets for the consumption of antibiotics for BRD and SRD. During the forecast period, we anticipate the arrival of numerous new players in the tulathromycin market in these two areas.
| Study Period | 2020-2032 | CAGR | 5% |
| Historical Period | 2020-2022 | Forecast Period | 2024-2032 |
| Base Year | 2023 | Base Year Market Size | USD XX Billion |
| Forecast Year | 2032 | Forecast Year Market Size | USD XX Billion |
The German tulathromycin market is expanding significantly and offers exciting potential. Tulathromycin, a veterinary antibiotic commonly used to treat bacterial and respiratory infections in animals, has become more popular in Germany due to several causes. The booming cattle business in Germany is one of the main factors driving the market. The nation is renowned for its robust agricultural industry, which includes raising cattle, swine, and poultry. Livestock farmers are putting more effort into keeping their animals healthy and productive as the demand for animal protein rises. Tulathromycin is essential in treating livestock respiratory disorders such as the bovine respiratory disease complex (BRD) and swine respiratory disease.
The well-developed German veterinary healthcare system comprises a network of veterinary clinics, hospitals, and experts. Producers of livestock and veterinarians are becoming more aware of the value of preventive healthcare practices and antibiotics when necessary. German veterinarians and livestock farmers favor tulathromycin since it is known to be an excellent antibiotic for the treatment and prevention of respiratory infections in animals.
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports
The German tulathromycin market is segmented based on animals.
Based on Animal, the market is segmented into cattle and swine.
Cattle dominates the market and is expected to register a CAGR of 6.6% over the forecast period. Tulathromycin treats and prevents bovine respiratory disease (BRD) caused by Mannheimia haemolytica, Pasteurella multocida, Histophilus somni, and Mycoplasma bovis in cattle. Respiratory disease plays a significant role in weaned calf mortality, and bovine respiratory disease (BRD) morbidity affects survivability and reduces dairy performance later in life.
